The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
100
Bone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)
CHU d'Amiens
Amiens, France, France
RECRUITINGCHU de Caen
Caen, France, France
Response to teclistamab at 12 weeks
response according to International Myeloma Working Group criteria
Time frame: at day 1 Cycle 4 (each cycle is 28 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Polyclinique du Parc Drevon
Dijon, France, France
RECRUITINGCH Annecy Genevois
Epagny Metz- Tessy, France, France
RECRUITINGCHU de Lille
Lille, France, France
RECRUITINGCentre Léon Bérard
Lyon, France, France
RECRUITINGCHU de Montpellier
Montpellier, France, France
RECRUITINGHôpital Saint-Louis
Paris, France, France
RECRUITINGHôpital Saint-Antoine
Paris, France, France
RECRUITINGHôpital Necker
Paris, France, France
RECRUITING...and 8 more locations